Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases

NCT03428477 is registered in ClinicalTrials.gov with Mark A Hull, PhD FRCP as lead sponsor.

NCT NCT03428477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03428477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases
Lead sponsor
Mark A Hull, PhD FRCP
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 2, 2018
Completion date
April 30, 2026
Enrollment
418 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, liver metastasis